Carrijo-Carvalho Linda Christian, Sant'ana Viviane Peracini, Foronda Annette Silva, de Freitas Denise, de Souza Carvalho Fabio Ramos
Department of Ophthalmology and Visual Sciences, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Department of Ophthalmology and Visual Sciences, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Surv Ophthalmol. 2017 Mar-Apr;62(2):203-218. doi: 10.1016/j.survophthal.2016.10.009. Epub 2016 Nov 9.
Acanthamoeba keratitis is a sight-threatening infectious disease. Resistance of the cystic form of the protozoan to biocides and the potential toxicity of chemical compounds to corneal cells are the main concerns related to long-term treatment with the clinically available ophthalmic drugs. Currently, a limited number of recognized antimicrobial agents are available to treat ocular amoebic infections. Topical application of biguanide and diamidine antiseptic solutions is the first-line therapy. We consider the current challenges when treating Acanthamoeba keratitis and review the chemical properties, toxicities, and mechanisms of action of the available biocides. Antimicrobial therapy using anti-inflammatory drugs is controversial, and aspects related to this topic are discussed. Finally, we offer our perspective on potential improvement of the effectiveness and safety of therapeutic profiles, with the focus on the quality of life and the advancement of individualized medicine.
棘阿米巴角膜炎是一种威胁视力的感染性疾病。原生动物的包囊形式对杀菌剂的耐药性以及化合物对角膜细胞的潜在毒性是与目前临床可用眼科药物长期治疗相关的主要问题。目前,可用于治疗眼部阿米巴感染的公认抗菌药物数量有限。局部应用双胍类和脒类防腐溶液是一线治疗方法。我们考虑了治疗棘阿米巴角膜炎时当前面临的挑战,并综述了现有杀菌剂的化学性质、毒性和作用机制。使用抗炎药物进行抗菌治疗存在争议,并讨论了与此主题相关的方面。最后,我们对治疗方案的有效性和安全性的潜在改进提出了看法,重点关注生活质量和个体化医学的进展。